Corneal cross-linking

GLOBAL DOWN SYNDROME FOUNDATION RECEIVES GRANT TO CORRECT SERIOUS EYE ISSUES & VISION LOSS IN PATIENTS WITH DOWN SYNDROME

Retrieved on: 
Monday, February 27, 2023
Keratoconus, Salah Foundation Children's Hospital, University, Diagnosis, Anna, UV, Paratriathlon, Cornea, FDA, Riboflavin, Patient, Down syndrome, Education, University of Colorado School of Medicine, Pediatric ophthalmology, Eye, Corneal cross-linking, Salah, Children's Hospital Colorado, Intellectual, Telescopic sight, Nursing, MD, Ophthalmology, Autism spectrum

Denver, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Global Down Syndrome Foundation (GLOBAL) announced today that it has received a transformative grant from The Salah Foundation .

Key Points: 
  • Denver, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Global Down Syndrome Foundation (GLOBAL) announced today that it has received a transformative grant from The Salah Foundation .
  • The condition, if left untreated, can lead to serious vision problems including blindness.
  • While keratoconus is not reversible, earlier detection can result in proactive treatment to halt the progression of the condition and can ultimately save the patient’s vision.
  • It is estimated that less than 2% of the general population suffers from keratoconus versus up to 30% in the Down syndrome population.

CXL Ophthalmics Announces $32 Million Series A Investment Round Led by AXA IM Alts, Through its Global Health Private Equity Strategy

Retrieved on: 
Friday, September 30, 2022
Research, Finance, FDA, Clinical Trials, Professional Services, Biotechnology, Pharmaceutical, Health, Optical, Science, Epithelium, Safety, ESG, Keratoconus, CXL, Risk, MD, FDA, Prevalence, UV, EPI, AXA, Astigmatism, IPE, Severe cognitive impairment, Infection, Patient, Cornea, Investment, Decision-making, MBA, Standard of care, Visual acuity, Diagnosis, Portal hypertensive gastropathy, Corneal cross-linking, Real assets, Pharmaceutical industry, Medical imaging, Medical device, Financial services, Infrastructure

CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced it has raised a $32 million Series A funding round led by AXA IM Alts through its Global Health Private Equity strategy plus a syndicate of individual investors, including leading cornea specialists.

Key Points: 
  • CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today announced it has raised a $32 million Series A funding round led by AXA IM Alts through its Global Health Private Equity strategy plus a syndicate of individual investors, including leading cornea specialists.
  • Todays funding announcement is an important step in achieving this goal, said Michael D. Webb, President and Chief Executive Officer of CXL Ophthalmics.
  • Curt LaBelle, MD, MBA, Head of Healthcare Private Equity at AXA IM Alts, said, Keratoconus is undertreated globally.
  • CXLO is developing a minimally-invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally.

CXL Ophthalmics Publishes Results of EpiSmart® Cross-Linking Phase 2 Clinical Trial for Keratoconus in Cornea

Retrieved on: 
Thursday, September 29, 2022
Biotechnology, Other Health, Health, Optical, Clinical Trials, Epithelium, Safety, Time, Journal, Keratoconus, CXL, Risk, MD, FDA, Prevalence, UV, EPI, Astigmatism, Patient, AES, Eye, Visual acuity, Opacity, Corneal cross-linking, Pharmaceutical industry, Medical imaging

CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking Phase 2 study for keratoconus in Cornea: The Journal of Cornea and External Disease.

Key Points: 
  • CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking Phase 2 study for keratoconus in Cornea: The Journal of Cornea and External Disease.
  • The Phase 2 trial is the largest study to-date of corneal cross-linking in the treatment of keratoconus, including 1,922 keratoconus patients.
  • Safety results suggest greater comfort during the acute healing period and fewer risks compared to the current standard of care.
  • The safety and efficacy of EpiSmart was investigated in a recently concluded 2,258-subject Phase 2 trial, and CXL Ophthalmics is preparing to initiate Phase 3 clinical trials for the treatment of keratoconus with EpiSmart.

PANORAMA EYECARE SPINS OFF NEW LASIK DIVISION AND ANNOUNCES PARTNERSHIP WITH DENVER BRONCOS

Retrieved on: 
Monday, August 8, 2022
Dallas, Rocky Mountains, Eye, Surgeon, Glaucoma, Technology, Bucking horse, Growth, Plastic, Business development, ASC, Phakic intraocular lens, ASC X12, Health, CO, Vance DeGeneres, Denver Broncos, UV, PEC, Partnership, Dallas Cowboys, Fort Collins, Colorado, Corneal cross-linking, MD, OD, SMILE, Panorama, Medical device, Telescopic sight, PRK, LASIK

FORT COLLINS, Colo., Aug. 8, 2022 /PRNewswire/ -- Panorama Eyecare (PEC), a physician-led management services organization and the largest comprehensive eye care organization in the Rocky Mountain region, announces the formation of Panorama LASIK a group of vision correction centers under the Panorama Eyecare. Panorama LASIK will be the LASIK Partner of the Denver Broncos.

Key Points: 
  • Panorama LASIK will be the LASIK Partner of the Denver Broncos.
  • Panorama LASIK launches as a division of Panorama Eyecare and LASIK Partner of the Denver Broncos.
  • Panorama LASIK is a division of the largest comprehensive eye care organization in the Rocky Mountain region, Panorama Eyecare (PEC).
  • Panorama LASIK will debut as the LASIK Partner of the Denver Broncos ahead of the Broncos first preseason game against the Dallas Cowboys on August 13th.

Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy

Retrieved on: 
Monday, March 14, 2022
Medical Devices, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Safety, Cornea, GKOS, Keratoconus, U.S. Securities and Exchange Commission, IEEE, Annual report, Corneal cross-linking, Glaucoma surgery, Retina, NYSE, Patient, Security (finance), Glaucoma, MIGS, Corporation, SEC, Pharmaceutical industry

Glaukos third-generation iLink therapy is a corneal cross-linking treatment designed to customize the therapeutic capabilities, streamline the patient experience and build upon Glaukos first-generation iLink therapy, known as iLink Epi-off, and its second-generation iLink investigational therapy, known as iLink Epi-on.

Key Points: 
  • Glaukos third-generation iLink therapy is a corneal cross-linking treatment designed to customize the therapeutic capabilities, streamline the patient experience and build upon Glaukos first-generation iLink therapy, known as iLink Epi-off, and its second-generation iLink investigational therapy, known as iLink Epi-on.
  • As we do with all of our platforms, we continue to drive subsequent generations of future innovation, and we are delighted to announce the commencement of this Phase 2 clinical program for our third-generation iLink therapy, said Thomas Burns, Glaukos president and chief executive officer.
  • Our third-generation iLink therapy builds upon our proven iLink platform therapies and we are delighted to have the opportunity to explore what this promising investigational therapy can do for keratoconus patients in our Phase 2 trials.
  • The third-generation iLink Phase 2 clinical program consists of two separate multi-center, randomized, controlled trials designed to evaluate the safety and efficacy of patient-specific, customized versus non-customized treatment patterns for corneal cross-linking and a new investigational laser-based bio-activation system, respectively.

Glaukos Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 11, 2020
Biotechnology, Medical devices, Health, Pharmaceutical, Optical, Ophthalmology, Eye surgery, Clinical medicine, Medical specialties, Blindness, Glaucoma, Corneal ectatic disorders, Corneal cross-linking, Cornea, Minimally invasive glaucoma surgery

Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

Key Points: 
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
  • The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm.
  • In corneal health, Glaukos proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions.
  • Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.